Regeneron Pharmaceuticals REGN
$904.35 +$1.45 (+0.16%)
Market closed · Nov 7, 9:50 pm ET · Last extended-hours $900.00 -0.48%
Open$887.22
Prev close$902.90
Day range$887.04 – $911.64
Volume1.12M
Market cap$93.55B
P/E (TTM)20.0
Dividend yield0.41%
REGN Stock News
Headlines matching Regeneron Pharmaceuticals or the REGN ticker, most recent first.
- J.P. Morgan Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $900
- Analysts' Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), Cytokinetics (CYTK) and Biohaven Ltd. (BHVN)
- HSBC Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $920 Positive
- J.P. Morgan Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $900 Positive
- Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $917
- Guggenheim Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,030 Positive
- Leerink Partners Downgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating, Announces Target Price $824 Negative
- Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $700
- Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $854 Negative
- A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $696 to $769
- Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Cuts Target Price to $730 Negative
- A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $750 to $960
- Goldman Sachs Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $965 Negative
- Guggenheim Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,000 Positive
- CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $875
No comments yet — be the first to weigh in on REGN.
Sign in to join the discussion.